In the Institute for Pulmonary Diseases and Tuberculosis, Novi Sad, a total number of 1500 patients was tested with a Kveim antigen prepared in this institute. Simultaneously these patients were tested with other antigens (SILTZBACH, BEHREND, DOUGLAS). Almost identical results could be found. In patients with sarcoidosis the Kveim test was positive in 60 to over 90%, depending on the stage of the disease. Within a cooperation 230 patients of the Research Institute for Pulmonary Diseases and Tuberculosis, Berlin-Buch, were tested with several Kveim antigens since 1972. 2/3 of these patients were suffering from sarcoidosis. All patients received Kveim antigen prepared in Novi Sad; one part of them was also tested with Kveim antigens prepared in Berlin-Buch. Dependent on the quality of the material processed the percentage of positive results was different. They varied from 65 to 30%. If there were less granulomas in the original material, as for the tissue of a spleen, used in Berlin-Buch, only 30% of sarcoidosis patients showed positive results. Therefore it is profitable to analyse the difficulties and the possibilities of improving the Kveim test as a valuable and rather simple diagnostical method.

Download full-text PDF

Source

Publication Analysis

Top Keywords

kveim antigens
12
tested kveim
12
institute pulmonary
8
pulmonary diseases
8
diseases tuberculosis
8
novi sad
8
patients tested
8
kveim antigen
8
antigen prepared
8
kveim test
8

Similar Publications

On the nature of sarcoidosis.

Eur J Intern Med

March 2012

Earle A Chiles Research Institute, Portland, OR, USA.

More than 140 years since its recognition as a clinical entity, sarcoidosis remains enigmatic. Its classification as a disease vs. a syndrome is uncertain.

View Article and Find Full Text PDF

This 'proof of concept' study was implemented in anticipation of identifying and testing a novel antigen of human origin as a potential immunogen in a paradigm that emphasizes immunomodulation and immune system reconstitution as requisites to the development of an effective human immunodeficiency virus (HIV)-acquired immune deficiency syndrome vaccine. Fifteen HIV-infected, highly active antiretroviral therapy (HAART) naive, otherwise healthy male seropositive patients were stratified by [CD4+] into 3 groups of 5 patients: group 1 >500/mm; group 2 > 250/mm but <500/mm; and group 3 < 250/mm. Five healthy male subjects were used as controls.

View Article and Find Full Text PDF

Potential etiologic agents in sarcoidosis.

Proc Am Thorac Soc

August 2007

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University, 5501 Hopkins Bayview Circle, Baltimore, MD 21224, USA.

The etiology of sarcoidosis remains uncertain. The hallmark of sarcoidosis is the epithelioid granuloma, which serves as a necessary starting point for considering disease etiology. Any etiologic agent of sarcoidosis must also explain the typical clinical behaviors and characteristic immunopathologic features of the disease.

View Article and Find Full Text PDF

We have collaborated with Japanese Sarcoidosis Society and Japanese Society of Respiratory Disease to provide a new diagnostic criteria of neurosarcoidosis. At least two of six examinations are important. These include bilateral hilar lymphadenopathy, abnormal uptake of 67Ga scintigraphy, broncho alveolar lavage fluid examination, elevated serum ACE, negative tuberculin reaction, and elevated serum or urinary calcium level.

View Article and Find Full Text PDF

Background: The introduction of foreign material into the skin can lead to sarcoidal reactions. Such a reaction is reported, consecutive to injections of botulic toxin A (Botox).

Case Report: A 57-year-old woman, noticed the occurrence of frontal and glabellar nodules, 3 weeks after the injection of botulic toxin A (Botox), for the correction of wrinkles.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!